Dr. Habte A Yimer

Claim this profile

Texas Oncology - Tyler

Studies Lymphoma
Studies Multiple Myeloma
20 reported clinical trials
38 drugs studied

Area of expertise

1Lymphoma
Habte A Yimer has run 10 trials for Lymphoma. Some of their research focus areas include:
Stage I
Stage IV
Stage III
2Multiple Myeloma
Habte A Yimer has run 5 trials for Multiple Myeloma.

Affiliated Hospitals

Image of trial facility.
Texas Oncology - Tyler
Image of trial facility.
(USO) Texas Oncology (Tyler)

Clinical Trials Habte A Yimer is currently running

Image of trial facility.

GM T Cell Therapy Long-Term Follow-Up

for Cancer

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Recruiting1 award Phase 2 & 3
Image of trial facility.

Cema-cel

for B-Cell Lymphoma

This is a randomized, open-label study in adult patients who have completed standard first line of therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. The study is conducted in 2 consecutive parts that will be enrolled continuously. In Part A of the study, participants with MRD are randomized to one of two treatment arms or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide administered with or without the anti-CD52 monoclonal antibody, ALLO-647. Part A will culminate with the selection of the lymphodepletion regimen to advance to Part B. Part B will evaluate the selected lymphodepletion regimen followed by cema-cel as compared with observation.
Recruiting1 award Phase 25 criteria

More about Habte A Yimer

Clinical Trial Related5 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Habte A Yimer has experience with
  • Rituximab
  • Lenalidomide
  • Selinexor
  • Tazemetostat
  • Dexamethasone
  • TAK-981

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Habte A Yimer specialize in?
Habte A Yimer focuses on Lymphoma and Multiple Myeloma. In particular, much of their work with Lymphoma has involved Stage I patients, or patients who are Stage IV.
Is Habte A Yimer currently recruiting for clinical trials?
Yes, Habte A Yimer is currently recruiting for 6 clinical trials in Tyler Texas. If you're interested in participating, you should apply.
Are there any treatments that Habte A Yimer has studied deeply?
Yes, Habte A Yimer has studied treatments such as Rituximab, Lenalidomide, Selinexor.
What is the best way to schedule an appointment with Habte A Yimer?
Apply for one of the trials that Habte A Yimer is conducting.
What is the office address of Habte A Yimer?
The office of Habte A Yimer is located at: Texas Oncology - Tyler, Tyler, Texas 75702 United States. This is the address for their practice at the Texas Oncology - Tyler.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.